Current and future treatments of secondary osteoporosis

被引：29

作者：

Soriano, Raquel ^{[1
,2
,3
,4
]}

Herrera, Sabina ^{[1
,2
,3
,4
]}

Nogues, Xavier ^{[1
,2
,3
,4
]}

Diez-Perez, Adolfo ^{[1
,2
,3
,4
]}

机构：

[1] Hosp del Mar, Dept Internal Med, Barcelona 08003, Spain

[2] Inst Hosp del Mar Invest Med, Barcelona, Spain

[3] Univ Autonoma Barcelona, E-08193 Barcelona, Spain

[4] Inst Carlos III, RETICEF, Madrid, Spain

来源：

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM | 2014年 / 28卷 / 06期

关键词：

osteoporosis; secondary osteoporosis; treatment; BONE-MINERAL DENSITY; ANDROGEN-DEPRIVATION THERAPY; INFLAMMATORY-BOWEL-DISEASE; CORTICOSTEROID-INDUCED OSTEOPOROSIS; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; ZOLEDRONIC ACID; VITAMIN-D; FRACTURE RISK; RHEUMATOID-ARTHRITIS;

D O I：

10.1016/j.beem.2014.09.004

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Osteoporosis is commonly associated with menopause and ageing. It can, however, also be caused by diseases, lifestyle, genetic diseases, drug therapies and other therapeutic interventions. In cases of secondary osteoporosis, a common rule is the management of the underlying condition. Healthy habits and calcium and vitamin D supplementation are also generally advised. In cases of high risk of fracture, specific antiosteoporosis medications should be prescribed. For most conditions, the available evidence is limited. Special attention should be paid to possible contraindications of drugs used for the treatment of postmenopausal or senile osteoporosis. Bisphosphonates are the most widely used drugs in secondary osteoporosis, and denosumab or teriparatide have been also assessed in some cases. Important research is needed to develop more tailored strategies, specific to the peculiarities of the different types of secondary osteoporosis. (C) 2014 Elsevier Ltd. All rights reserved.

引用

页码：885 / 894

页数：10

共 124 条

[1]

A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease [J].